SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Krystal Biotech, Inc. (KRYS) trades at a trailing P/E of 36.4, forward P/E of 35.3. Trailing earnings yield is 2.75%, forward earnings yield 2.83%. PEG 0.28 (Peter Lynch undervalued ≤1.0). Graham Number is $81.91.
Criteria proven by this page:
- VALUE (57/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 35.3 (down from trailing 36.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.28 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 2.75% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 2.83% as earnings recover.
- Analyst consensus target $311.00 (+15.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 85/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
57/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — KRYS
Valuation Multiples
P/E (TTM)36.4
Forward P/E35.3
PEG Ratio0.28
Forward PEG3.02
P/B Ratio6.11
P/S Ratio19.34
EV/EBITDA41.9
Per Share Data
EPS (TTM)$7.08
Forward EPS (Est.)$7.64
Book Value / Share$42.14
Revenue / Share$13.44
FCF / Share$6.53
Yields & Fair Value
Earnings Yield2.75%
Forward Earnings Yield2.83%
Dividend Yield0.00%
Graham Number$81.91
SharesGrow IV$949.71 (+251.7%)
Analyst Target$311.00 (+15.2%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-39.6 |
0.00 |
157.41 |
0.00 |
- |
| 2017 |
-7.1 |
-0.02 |
1.14 |
0.00 |
- |
| 2018 |
-21.4 |
0.62 |
2.06 |
226.68 |
- |
| 2019 |
-46.1 |
-1.95 |
4.34 |
0.00 |
- |
| 2020 |
-35.0 |
-0.82 |
3.86 |
0.00 |
- |
| 2021 |
-22.3 |
-0.27 |
2.62 |
0.00 |
- |
| 2022 |
-14.4 |
-0.19 |
3.87 |
0.00 |
- |
| 2023 |
308.2 |
-2.87 |
4.33 |
66.45 |
- |
| 2024 |
50.2 |
0.07 |
4.73 |
15.42 |
- |
| 2025 |
34.8 |
0.27 |
5.85 |
18.34 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.27 |
$0.00 |
$-1.15M |
- |
| 2017 |
$-1.48 |
$0.00 |
$-7.92M |
- |
| 2018 |
$-0.97 |
$1.03M |
$-10.89M |
-1060.3% |
| 2019 |
$-1.20 |
$0.00 |
$-19.09M |
- |
| 2020 |
$-1.71 |
$0.00 |
$-32.17M |
- |
| 2021 |
$-3.13 |
$0.00 |
$-69.57M |
- |
| 2022 |
$-5.49 |
$0.00 |
$-139.98M |
- |
| 2023 |
$0.39 |
$50.7M |
$10.93M |
21.6% |
| 2024 |
$3.00 |
$290.52M |
$89.16M |
30.7% |
| 2025 |
$6.84 |
$389.13M |
$204.83M |
52.6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$7.64 |
$5.57 – $9.24 |
$524.35M |
$472.59M – $575.72M |
8 |
| 2027 |
$9.95 |
$5.03 – $15.36 |
$671.48M |
$574.67M – $768.29M |
7 |
| 2028 |
$13.46 |
$8.34 – $27.13 |
$899.45M |
$872.5M – $926.41M |
5 |
| 2029 |
$20.30 |
$15.80 – $26.05 |
$1.15B |
$951.31M – $1.4B |
1 |
| 2030 |
$27.11 |
$21.11 – $34.80 |
$1.45B |
$1.2B – $1.77B |
1 |
